MCID: HPT021
MIFTS: 68

Hepatitis

Categories: Gastrointestinal diseases, Liver diseases, Genetic diseases, Rare diseases, Immune diseases, Skin diseases, Infectious diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 38 12 29 52 41 14 69
Chronic Persistent Hepatitis 12 52 69
Acute Hepatitis 12 29 69
Hepatitis, Chronic 42 69
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Chronic Hepatitis 12
Hepatitis Chronic 52
Hepatitis, Animal 69
Animal Hepatitis 12
Hepatitis a 69

Classifications:



Summaries for Hepatitis

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. hepatitis is an inflammation of the liver. viruses cause most cases of hepatitis. the type of hepatitis is named for the virus that causes it; for example, hepatitis a, hepatitis b or hepatitis c. drug or alcohol use can also cause hepatitis. in other cases, your body mistakenly attacks healthy cells in the liver. some people who have hepatitis have no symptoms. others may have loss of appetite nausea and vomiting diarrhea dark-colored urine and pale bowel movements stomach pain jaundice, yellowing of skin and eyes some forms of hepatitis are mild, and others can be serious. some can lead to scarring, called cirrhosis, or to liver cancer. sometimes hepatitis goes away by itself. if it does not, it can be treated with drugs. sometimes hepatitis lasts a lifetime. vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis c virus and toxoplasmosis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are NF-kappaB Signaling and Immune response IFN alpha/beta signaling pathway. The drugs Aluminum hydroxide and Aluminum sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes.

Wikipedia : 72 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1557)
id Related Disease Score Top Affiliating Genes
1 hepatitis c virus 32.7 CD81 CLDN1 CLDN6 CLDN9 GPT HAVCR2
2 toxoplasmosis 30.2 IFNA1 TNF
3 hereditary hemorrhagic telangiectasia 29.6 AFP GPT IFNA1 IFNA2 LAMTOR5 NR5A2
4 hemolytic-uremic syndrome 29.2 AFP GPT HAVCR1 HAVCR2 IFNA2 TNF
5 hepatitis c 12.3
6 autoimmune hepatitis 12.3
7 hepatitis b 12.3
8 viral hepatitis 12.3
9 hepatitis d 12.3
10 hepatitis a 12.3
11 hepatic veno-occlusive disease 12.3
12 alcoholic hepatitis 12.2
13 hepatic encephalopathy 12.2
14 hepatic lipase deficiency 12.2
15 hepatic venoocclusive disease with immunodeficiency 12.1
16 hepatitis e 12.1
17 congenital hepatic fibrosis 12.1
18 renal-hepatic-pancreatic dysplasia 12.1
19 non-a-e hepatitis 12.1
20 hepatic adenoma, somatic 11.9
21 epstein-barr virus hepatitis 11.9
22 granulomatous hepatitis 11.9
23 porphyria, acute hepatic 11.9
24 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.9
25 renal-hepatic-pancreatic dysplasia 2 11.9
26 polycystic kidney disease 4, with or without hepatic disease 11.9
27 hepatic coma 11.9
28 fulminant viral hepatitis 11.8
29 drug-induced hepatitis 11.8
30 hepatic tuberculosis 11.8
31 cpt deficiency, hepatic, type ia 11.8
32 hepatic flexure cancer 11.8
33 renal-hepatic-pancreatic dysplasia 1 11.8
34 hepatic infarction 11.8
35 hepatic angiomyolipoma 11.8
36 liver disease 11.8
37 sclerosing hepatic carcinoma 11.8
38 hepatic vascular disease 11.8
39 hepatocellular carcinoma 11.7
40 primary hepatic neuroendocrine carcinoma 11.7
41 isolated congenital hepatic fibrosis 11.7
42 coach syndrome 11.7
43 acute liver failure 11.7
44 glycogen storage disease iv 11.7
45 hepatic failure, early-onset, and neurologic disorder due to cytochrome c oxidase deficiency 11.6
46 chronic end-stage hepatitis c 11.6
47 hepatic cystic hamartoma 11.6
48 hepatitis b reinfection following liver transplantation 11.6
49 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.6
50 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 11.6

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, pruritus, gastrointestinal gas, hepatocellular jaundice, lameness, animal

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 781)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Aluminum sulfate Approved Phase 4,Phase 3,Phase 1,Phase 2 10043-01-3
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
6
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
8
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
9
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
10
Isoniazid Approved Phase 4,Phase 3,Phase 2 54-85-3 3767
11
Pyrazinamide Approved Phase 4,Phase 2,Phase 3 98-96-4 1046
12
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
13
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
16
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
17
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
18
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
19
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
21
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
22
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
23
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
24
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
25
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
28
Ethiodized oil Approved Phase 4,Phase 3,Phase 2 8008-53-5
29
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
30
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
31
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
32
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
33
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
34
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
35
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128-13-2 31401
36
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
37
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
38
Insulin Glargine Approved Phase 4 160337-95-1
39
Insulin-glulisine Approved Phase 4 207748-29-6
40
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
41
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
42
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
43
Thrombin Approved Phase 4,Phase 3,Phase 1
44
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
45
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
46
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
47
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
48
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
49
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
50 Simethicone Approved Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 4053)

id Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
5 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
6 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
7 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
8 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
9 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
10 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
11 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
12 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
13 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
14 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
15 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
16 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
17 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
18 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
19 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
20 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
21 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
22 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
23 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
24 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
25 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
26 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
27 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
28 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
29 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
30 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4 Entecavir maleate tablets;blank Baraclude tablets;Blank maleate entecavir tablets;Baraclude tablets
31 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
32 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
33 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4 Telbivudine, Adefovir dipivoxil
34 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
35 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
36 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
37 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
38 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
39 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
40 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
41 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
42 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
43 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
44 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
45 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
46 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
47 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
48 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
49 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
50 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis, chronic

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

id Genetic test Affiliating Genes
1 Acute Hepatitis 29
2 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

39
Liver, T Cells, Testes, Kidney, Bone, Brain, B Cells

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 26588)
id Title Authors Year
1
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA. ( 28077172 )
2017
2
Hepatitis B and C in Tonkolili Province, Sierra Leone. ( 28952444 )
2017
3
Frequency and role of NKp46 and NKG2A in hepatitis B virus infection. ( 28328926 )
2017
4
Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues. ( 28440732 )
2017
5
The Histopathological Features and CT/MRI Imaging Performances in Hepatic Angiomyolipoma Patients. ( 28809731 )
2017
6
Psoriasiform papules, condyloma lata, lung nodules and hepatitis: the enormous variability of secondary syphilis manifestations. ( 28476906 )
2017
7
Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331]. ( 28893453 )
2017
8
Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B: A cross-sectional study of diagnostic accuracy. ( 28514295 )
2017
9
Lethal neonatal hyperammonemia in severe ornithine transcarbamylase (OTC) deficiency compounded by large hepatic portosystemic shunt. ( 27832417 )
2017
10
Immune Thrombocytopenic Purpura and Hemolytic Anemia Secondary to Hepatitis A. ( 28875001 )
2017
11
Diffusion-weighted imaging of the pericholecystic hepatic parenchyma for distinguishing acute and chronic cholecystitis. ( 28861635 )
2017
12
Variations in IL-1R1 Gene Influence Risk for Hepatitis B Virus Infection of Children in a Han Chinese population. ( 28027994 )
2017
13
Acquired Hemophilia A After Hepatic Yttrium-90 Radioembolization: A Case Report. ( 28767473 )
2017
14
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. ( 27797398 )
2017
15
Amelioration of Ethanol-Induced Hepatitis by Magnesium Isoglycyrrhizinate through Inhibition of Neutrophil Cell Infiltration and Oxidative Damage. ( 28951632 )
2017
16
Co-existence of the double inferior vena cava with complex interiliac venous communication and aberrant common hepatic artery arising from superior mesenteric artery: a case report. ( 28832091 )
2017
17
Prevalence of G6PD deficiency in Children with Hepatitis A. ( 28875002 )
2017
18
Central pontine myelinolysis in a type 1 diabetes patient with chronic hepatitis. ( 28583270 )
2017
19
A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. ( 28223128 )
2017
20
Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness. ( 28754919 )
2017
21
Autoimmune Hepatitis - Primary Biliary Cirrhosis Overlap Syndrome. ( 28892963 )
2017
22
Adult-onset Still's disease-like condition due to alcoholic hepatitis and vitamin B deficiency. ( 28691376 )
2017
23
Kidney Injury due to Ureteral Obstruction Caused by Compression from Infected Simple Hepatic Cyst. ( 28626377 )
2017
24
Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy. ( 28782876 )
2017
25
Molecular characterization of AID-mediated reduction of hepatitis B virus transcripts. ( 28779685 )
2017
26
Hepatic Epithelioid Hemangioendothelioma - a Rare Tumor and Diagnostic Dilemma. ( 28652454 )
2017
27
Detection of rat hepatitis E virus in wild Norway rats (Rattus norvegicus) and Black rats (Rattus rattus) from 11 European countries. ( 28888650 )
2017
28
Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway. ( 28811235 )
2017
29
Redefining successful treatment of severe alcoholic hepatitis. ( 28741287 )
2017
30
Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1). ( 28211090 )
2017
31
Endoplasmic reticulum stress restrains hepatocyte growth factor expression in hepatic stellate cells and rat acute liver failure model. ( 28844859 )
2017
32
Association of Autoimmune Hepatitis and Celiac Disease: Role of Gluten-Free Diet in Reversing Liver Dysfunction. ( 28491884 )
2017
33
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. ( 28946736 )
2017
34
Polymorphisms of chemokine receptor genes and clearance of hepatitis C virus infection in Chinese population. ( 28456591 )
2017
35
Lack of Ser267Phe variant of sodium taurocholate cotransporting polypeptide among Moroccans regardless of hepatitis B virus infection status. ( 28125961 )
2017
36
Multiple small intestinal perforations in a patient with Hepatitis B Virus-associated Polyarteritis Nodosa. ( 28878877 )
2017
37
Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants. ( 28082397 )
2017
38
p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress. ( 28286271 )
2017
39
Primary Hepatic Angiosarcoma Mimicking Multifocal Liver Abscess with Disseminated Intravascular Coagulation and Hemoperitoneum. ( 28680781 )
2017
40
The future of liver transplantation for viral hepatitis. ( 28052618 )
2017
41
Sensitive Genotyping of Foodborne-Associated Human Noroviruses and Hepatitis A Virus Using an Array-Based Platform. ( 28930175 )
2017
42
Hepatitis C virus status in hemodialysis patients in Menoufia Government, Egypt, five years apart: Do we have any improvement? ( 28937073 )
2017
43
A Joint Society statement for elimination of viral hepatitis. ( 28051786 )
2017
44
Retinoid BMS411 (4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl) carbonyl] amino} benzoic acid), a potential inhibitor of NS5A protein of hepatitis C virus, a candidate for combined therapy of hepatitis C infection. ( 28523927 )
2017
45
MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. ( 28098912 )
2017
46
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. ( 28083718 )
2017
47
Genotypes and subgenotypes of hepatitis B virus circulating in an endemic area in Peru. ( 28948365 )
2017
48
Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. ( 28948495 )
2017
49
Combination therapies for primary hepatic neuroendocrine carcinoma: a case report. ( 28895097 )
2017
50
Hypermethylation of the N-Myc Downstream-Regulated Gene 2 Promoter in Peripheral Blood Mononuclear Cells is Associated with Liver Fibrosis in Chronic Hepatitis B. ( 28202850 )
2017

Variations for Hepatitis

Copy number variations for Hepatitis from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.75 HAVCR1 HAVCR2 IFNA1 TNF
2
Show member pathways
11.54 IFNA1 IFNA2 TNF
3 11.34 CD81 CLDN1 CLDN6 CLDN9 IFNA1 IFNA2

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 bicellular tight junction GO:0005923 8.8 CLDN1 CLDN6 CLDN9

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.56 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 LMBRD1
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.51 HAVCR2 TNF
3 humoral immune response GO:0006959 9.5 IFNA1 IFNA2 TNF
4 T cell activation involved in immune response GO:0002286 9.49 IFNA1 IFNA2
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.48 IFNA1 IFNA2
6 natural killer cell activation involved in immune response GO:0002323 9.46 IFNA1 IFNA2
7 positive regulation of chemokine production GO:0032722 9.43 HAVCR2 TNF
8 cell-cell junction organization GO:0045216 9.43 CLDN1 CLDN6 CLDN9
9 negative regulation of glucose import GO:0046325 9.4 LMBRD1 TNF
10 protein localization to lysosome GO:0061462 9.37 CD81 LAMTOR5
11 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN1 CLDN6 CLDN9
12 viral entry into host cell GO:0046718 9.1 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 SCARB1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNA1 IFNA2 IFNL4 TNF
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 virus receptor activity GO:0001618 9.1 CD81 CLDN1 CLDN6 CLDN9 HAVCR1 SCARB1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....